[1]赵淑丽,楚天舒.血浆致动脉硬化指数在冠心病中的应用及研究进展[J].心血管病学进展,2015,(6):721-725.[doi:10.3969/j.issn.1004-3934.2015.06.016]
 ZHAO Shuli,CHU Tianshu.Application and Research Progress of Atherogenic Index of Plasma in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2015,(6):721-725.[doi:10.3969/j.issn.1004-3934.2015.06.016]
点击复制

血浆致动脉硬化指数在冠心病中的应用及研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2015年6期
页码:
721-725
栏目:
综述
出版日期:
2016-06-20

文章信息/Info

Title:
Application and Research Progress of Atherogenic Index of Plasma in Coronary Atherosclerotic Heart Disease
作者:
赵淑丽楚天舒
昆明医科大学第二附属医院心血管内科,云南 昆明 650000
Author(s):
ZHAO Shuli CHU Tianshu
Department of Cardiology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, Yunnan, China
关键词:
述。血浆致动脉硬化指数 血脂异常 冠心病
Keywords:
atherogenic index of plasma dyslipidemia coronary atherosclerotic heart disease
分类号:
R541.4
DOI:
10.3969/j.issn.1004-3934.2015.06.016
文献标志码:
A
摘要:
冠状动脉粥样硬化性心脏病是一种严重威胁人类健康的常见病、多发病,在发达国家已成为人口死亡的主要原因。血脂异常是动脉粥样硬化的最重要危险因素,经典单纯单项血脂指标异常已不能完全解释和预测心血管病发病和转归的规律,血浆致动脉硬化指数作为一项新的血脂综合指标,可以进行初步预测冠状动脉病变,并早期诊断及评估冠心病的发生,具有较强的应用及临床实用价值,明显优于现有的传统单项血脂指标。现就血浆致动脉硬化指数在冠心病中的应用及研究进展予以综述。
Abstract:
Coronary atherosclerotic heart disease is a serious threat to human health of common disease, frequently-occurring disease, has become the leading cause of death in population in developed countries. Dyslipidemia is the most important risk factor for atherosclerosis. Traditional single index of lipid abnormalities can not fully explain and predict cardiovascular disease incidence and the law of outcome. Atherogenic index of plasma as a new lipid comprehensive index, with strong application and clinical practical value, is superior to the existing traditional single blood fat index, can conduct a preliminary prediction of coronary aretery lesions, and early diagnosis and assessment of the occurrence of coronary heart disease. Here is to review the application and research progress of atherogenic index of plasma in coronary atherosclerotic heart disease.

参考文献/References:

[1] Chen J, Chen MH, Guo YL, et al. Plasma big endothelin-1 level and the severity of new-onset stable coronary artery disease[J]. J Atheroscler Thromb,2015, 22(2):126-135.
[2] Gaszner B, Lenkey Z, Illyés M,et al. Comparison of aortic and carotid arterial stiffness parameters in patients with verified coronary artery disease[J].Clin Cardiol, 2012,35(1):26-31.
[3] Liao J, Farmer J. Arterial stiffness as a risk factor for coronary artery disease[J]. Curr Atheroscler Rep,2014,16(2):387.
[4] Weil BR, Westby CM, Greiner JJ, et al. Elevated endothelin-1 vasoconstrictor tone in prehypertensive adults[J]. Can J Cardiol,2012,28(3):347-353.
[5] Teramoto T, Sasaki J, Ueshima H, et al. Goals of dyslipidemia management[J]. J Atheroscler Thromb,2007,14(5):209-212.
[6] Dobiásová M, Frohlich J. The plasma parameter Log(TG/HDL-C)as an atherogenic index:correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma(FER(HDL))[J]. Clin Biochem,2001,34(7):583-588.
[7] Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes[J]. Clin Chem,2004,50(7):1184-1188.
[8] Rosolova H, Dobiasova M, Soska V, et al. Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma[J]. Coret Vasa, 2014,56(2):133-139.
[9] Carey VJ, Bishop L, Laranjo N,et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control[J]. Am J Cardiol,2010, 106(6):757-763
[10] Hong LF, Li XL, Luo SH, et al. Association of fibrinogen with severity of stable coronary artery disease in patients with type 2 diabetic mellitus[J]. Dis Markers,2014, 2014:485687.
[11] Wu N, Ma F, Guo Y,et al.Association of N-terminal pro-brain natriuretic peptide with normal left ventricular ejection fraction[J]. Chin Med J,2014,127(4):627-632.
[12] Hong LF, Li XL, Luo SH, et al. Relation of leukocytes and its subsets counts with the severity of stable coronary artery disease in patients with diabetic mellitus[J]. PLoS One,2014,9(3): e90663.
[13] Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease[J]. Circulation,2012,125(2):233-240.
[14] Leaman DM, Brower RW, Meester GT, et al. Coronary artery atherosclerosis:severity of the disease, severity of angina pectoris and compromised left ventricular function[J]. Circulation,1981,63(2):285-299.
[15] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease[J]. Am J Cardiol,1983,51(3):606.
[16] Guideline for Coronary Angiography. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures(subcommittee on coronary angiography)[J]. J Am Coll Cardiol,1987,10(4):935-950.
[17] Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score:an angiographic tool grading the complexity of coronary artery disease[J]. Eurolntervention,2005,1(2):219-227.
[18] Teramoto T, Sasaki J, Ishibashi S, et al. Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society(JAS)guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version[J]. J Atheroscler Thromb,2013,20(10):733-742.
[19] Dobiásová M. Atherogenic index of plasma[log(triglycerides/HDL-cholesterol)]: theoretical and practical implications[J].Clin Chem,2004,50(7):1113-1115.
[20] 郑家胜,俎德玲,诸葛毅,等. 冠心病血浆致动脉硬化指数的临床研究[J].心电与循环,2013,32(4):263-265.
[21] Sharma P, Purohit P, Gupta R. Cardiac risk factors in descendants of patients with history of coronary artery desease(CAD): an evaluation focusing on small dense low density lipoprotein cholesterol(sdLDLc)and high density lipoprotein cholesterol(HDLc)[J]. Indian J Biochem Biophys,2013,50(5):453-461.
[22] Nishikura T, Koba S, Yokota Y, et al. Elevated small dense low-density liporprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease[J]. J Atheroscler Thromb,2014,21(8):755-767.
[23] Yildiz G, Hür E,ozcicek A, et al. The mean platelet volume and atherogenic index of plasma in nondipper normotensive individuals compared to dippers[J]. Clin Exp Hypertens,2013,35(1):35-39.
[24] 周筱琼,于小妹,叶雄伟,等. 高脂血症患者血浆致动脉粥样硬化指数与血栓形成危险因子的相关性[J]. 中国动脉硬化杂志,2010,18(10):799-802.
[25] 俎德玲,诸葛毅,蒋一鸣,等.血浆致动脉硬化指数在老年高血压的应用评价[J].中国卫生检验杂志,2012,22(12):2865-2867.
[26] Dobiásová M, Frohlich J, Sedová M, et al. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography[J]. J Lipid Res,2011,52(3):566-571.
[27] Nwagha UI, Ikekpeazu EJ, Ejezie FE, et al. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria[J]. Afr Health Sci,2010,10(3):248-252.
[28] Onat A,Can G,Kaya H,et al.“Atherogenic index of plasma”(log10 triglyceride/high-density lipoprotein-cholesterol)predicts high blood pressure, diabetes, and vascular events[J]. J Clin Lipidol,2010,4(2):89-98.
[29] 宋媛媛.动态动脉硬化指数及血浆致动脉硬化指数与冠心病的相关性[D].河北:河北医科大学,2013.
[30] 赵少华. AIP及non-HDL-C水平与冠状动脉病变程度的关系[D].山西: 山西医科大学第一临床学院,2012.
[31] Paramsothy P, Katz R, Owens DS, et al. Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium(from the Multi-Ethnic Study of Atherosclerosis [MESA])[J]. Am J Cardiol,2010,105(3):352-358.
[32] Yunke Z, Guoping L, Zhenyue C.Triglyceride-to-HDL cholesterol ratio. Predictive value for CHD severity and new-onset heart failure[J].Herz,2014,39(1):105-110.
[33] 高枫,苏伟.血浆致动脉硬化指数对冠状动脉病变严重程度的评估意义[J].交通医学,2015,29(1):50-52.

备注/Memo

备注/Memo:
作者简介:赵淑丽(1987—),硕士,主要从事心血管疾病研究。Email:zhaoshuli0201@163.com 通信作者:楚天舒(1966—),主任医师,主要从事心血管疾病研究。Email:chutianshu2014@163.com
更新日期/Last Update: 2016-06-20